Showing 2701-2710 of 5646 results for "".
- Novartis and Microsoft Announce Collaboration to Transform Medicine with Artificial Intelligencehttps://modernod.com/news/novartis-and-microsoft-announce-collaboration-to-transform-medicine-with-artificial-intelligence/2476932/Novartis announced a step in reimagining medicine by founding the Novartis AI innovation lab and by selecting Microsoft as its strategic AI and data-science partner for this effort, according to a company news release. The new lab aims to bolster Novartis AI capabilities from research through com
- Ocular Therapeutix Announces Permanent J-Code for Dextenza Effective October 1, 2019https://modernod.com/news/ocular-therapeutix-announces-permanent-j-code-for-dextenza-effective-october-1-2019/2476930/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code for Dextenza (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use. Under the Healthcare Common Procedure Coding System (HCPCS), the J-code (J1096) will
- Ocugen and CanSinoBIO Enter Strategic Partnership for Gene Therapy Co-Development and Manufacturinghttps://modernod.com/news/ocugen-and-cansinobio-enter-strategic-partnership-for-gene-therapy-co-development-and-manufacturing/2476929/Ocugen has entered into a strategic partnership with CanSino Biologics on Ocugen’s gene therapy pipeline product candidates for inherited retinal diseases, which are currently in development with Schepens Eye Research Institute of Massachusetts Eye and Ear, an affiliate of Harvard Medical Schoo
- Second Sight Announces $2.4 Million, 4-Year Grant from NIH to Develop Spatial Localization and Mapping Technologyhttps://modernod.com/news/second-sight-announces-2-4-million-4-year-grant-from-nih-to-develop-spatial-localization-and-mapping-technology/2476926/Second Sight Medical Products announced receipt of a $2.4 million, 4-year grant from the National Institutes of Health (NIH) to develop spatial localization and mapping technology (SLAM). A joint collaboration with the Johns Hopkins University Applied Physics Laboratory (APL), the initiative is i
- Product Specific J-Code for Omeros’ Omidria is Now in Effecthttps://modernod.com/news/product-specific-j-code-for-omeros-omidria-is-now-in-effect/2476927/Omeros announced that the product specific J-code for Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% is now effective. Omidria is Omeros’ commercial drug marketed for use during cataract surgery to prevent miosis and reduce postoperative pain. The new permanent J-code f
- Bausch + Lomb Enters Licensing Agreement With Intraocular Lens Design Group Tatvum Researchhttps://modernod.com/news/bausch-lomb-enters-licensing-agreement-with-intraocular-lens-design-group-tatvum-research/2476928/Bausch + Lomb announced that it has entered into a licensing agreement with Tatvum Research, a company focused on IOL development and design. Financial terms of the deal were not disclosed. The agreement provides Bausch + Lomb with worldwide commercial rights to new IOL designs for
- Santen Expands Into Surgical Devices and Publishes Real-World Evidence in Dry Eye Diseasehttps://modernod.com/news/santen-expands-into-surgical-devices-and-publishes-real-world-evidence-in-dry-eye-disease/2476923/In addition to launching a new monofocal, hydrophobic IOL, xact Mono-EDoF, a panel of experts including Ike K. Ahmed, reviewed current surgical techniques and introduced Santen’s Preserflo MicroShunt device at the recent ESCRS meeting in Paris. Preserflo MicroShunt is a surgical dev
- Ocular Therapeutix Announces First Patient Dosed in Phase 3 Clinical Trial of Dextenza for the Treatment of Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-3-clinical-trial-of-dextenza-for-the-treatment-of-allergic-conjunctivitis/2476914/Ocular Therapeutix announced that it has dosed the first patients in its phase 3 clinical trial of Dextenza for the treatment of symptoms of allergic conjunctivitis. Allergic conjunctivitis refers to inflammation of the conjunctiva of the eye caused by an allergic reaction–generally from airborne
- Novo Nordisk’s Rybelsus Gains FDA Approval as First Oral GLP-1 Receptor Agonist for Type 2 Diabeteshttps://modernod.com/news/novo-nordisks-rybelsus-gains-fda-approval-as-first-oral-glp-1-receptor-agonist-for-type-2-diabetes/2476907/The FDA announced Friday the approval of Novo Nordisk’s Rybelsus (semaglutide) to improve control of blood glucose in adults with type 2 diabetes, along with diet and exercise, making it the first oral GLP-1 receptor agonist cleared in the US. Lisa Yanoff, acting director of the Division of
- Canon Xephilio OCT-A1 Device Receives FDA 510(k) Clearancehttps://modernod.com/news/canon-xephilio-oct-a1-device-receives-fda-510k-clearance/2476889/Expanding the company’s lineup of eye care product offerings, Canon USA announced the new intuitive Xephilio OCT-A1 device. This device features automated acquisition functionality, which makes it easy to use, allowing healthcare professionals to obtain high